Table 1.
Patient demographics and molecular/clinical characteristics
| Characteristic | YM155 3.6–12 mg/m2 (N=22, phase I) | YM155 10 mg/m2 (N=19, phase II) |
|---|---|---|
| Sex | ||
| Male | 10 (45%) | 11 (58%) |
| Female | 12 (55%) | 8 (42%) |
| Histology | ||
| Lung cancer | ||
| Adenocarcinoma | 11 (50%) | 14 (74%) |
| Bronchioalveolar (BAC) | 3 (14%) | 1 (5%) |
| Squamous cell carcinoma | 3 (14%) | 2 (11%) |
| Large cell | 1 (4.5%) | 2 (11%) |
| Small cell | 1 (4.5%) | |
| Adenoid cystic | 1 (4.5%) | |
| Angiosarcoma | 1 (4.5%) | |
| Unknown origin | 1 (4.5%) | |
| Mutational status (18 NSCLC patients on phase I) | ||
| EGFR | ||
| Mutated | 2 (11%) | 1 (5%) |
| Wild-type | 15 (83%) | 16 (84%) |
| Not done | 1 (6%) | 2 (11%) |
| KRAS | ||
| Mutated | 8 (44%) | 3 (16%) |
| Wild-type | 8 (44%) | 14 (74%) |
| Not done | 2 (11%) | 2 (10%) |
| Ethnicity | ||
| White | 13 (59%) | 14 (74%) |
| African American | 1 (4%) | 3 (16%) |
| Asian | 5 (23%) | 1 (5%) |
| Hispanic/Latino | 3 (14%) | 1 (5%) |
| Age | ||
| Median age (years) | 62 | 59 |
| Range | 38–79 | 41–74 |
| No. of prior regimens | ||
| 0 | 9 (41%) | 0 (100%) |
| 1 | 7 (32%) | |
| >1 | 6 (27%) | |
EGFR, epidermal growth factor receptor; KRAS, Kirsten RNA-associated rat Sarcoma 2 virus gene.